Egyptian Retina Journal

ORIGINAL ARTICLE
Year
: 2018  |  Volume : 5  |  Issue : 1  |  Page : 15--20

Benefits of anti-vascular endothelial growth factor therapy for diabetic macular edema with and without vitreomacular adhesions


Yasmine Salah Salem1, Ahmed Abdel El Alim Mohamed2, Mohamed Hanafy Hashem2, Mohamed Maher El Hefny1 
1 Department of Ophthalmology, Research Institute of Ophthalmology, Giza, Egypt
2 Department of Ophthalmology, Faculty of Medicine, Ain Shams University, Cairo, Egypt

Correspondence Address:
Dr. Yasmine Salah Salem
Research Institute of Ophthalmology, Giza
Egypt

Purpose: We aimed to evaluate the effect of vitreomacular adhesion (VMA) in visual and anatomic outcomes in patients with diabetic macular edema (DME) after intravitreal injection of ranibizumab (Lucentis®). Patients and Methods: This was a prospective cohort study that included thirty eyes of DME patients, divided into two groups according to their spectral-domain-optical coherence tomography image analysis at the baseline visit to identify the presence (VMA+) or absence (VMA−) of VMA. Patients with any degree of vitreomacular traction were not included in this study. VMA was classified by the size of adhesion into either focal (<1500 mm) or broad (>1500 mm). All patients received monthly 0.5 mg of intravitreal ranibizumab injection for 6 months. Patients were observed monthly for a 6-month period and their best-corrected visual acuity (BCVA) and central macular thickness (CMT) were recorded. The incidence of posterior vitreous detachment (PVD) was observed. Results: Compared with baseline, there was a significant decrease in CMT after 6 months by 151.46 ± 121.47 and 139.33 ± 144.23 μm in VMA+ and VMA− groups, respectively (P = 0.681). The mean average improvement in BCVA was 10.21 ± 6.33 and 6.68 ± 6.35 letters in the VMA+ and VMA− groups, respectively. The difference between the two groups was statistically significant (P = 0.007). At 6 months, among the 15 eyes of VMA+ at baseline, 4 eyes demonstrated PVD and 11 eyes showed no change in VMA status. Conclusion: Patients having DME with VMA may achieve higher visual gain with anti-vascular endothelial growth factor therapy. Presence of VMA should not preclude patients with DME from receiving anti-vascular endothelial growth factor therapy.


How to cite this article:
Salem YS, Mohamed AA, Hashem MH, El Hefny MM. Benefits of anti-vascular endothelial growth factor therapy for diabetic macular edema with and without vitreomacular adhesions.Egypt Retina J 2018;5:15-20


How to cite this URL:
Salem YS, Mohamed AA, Hashem MH, El Hefny MM. Benefits of anti-vascular endothelial growth factor therapy for diabetic macular edema with and without vitreomacular adhesions. Egypt Retina J [serial online] 2018 [cited 2019 Apr 26 ];5:15-20
Available from: http://www.egyptretinaj.com/article.asp?issn=2347-5617;year=2018;volume=5;issue=1;spage=15;epage=20;aulast=Salem;type=0